Table 1 Characteristics of the patients with IDU-IE and non-IDU-IE admitted between 2008 and 2017
Clinical characteristics | IDU-IE (n = 165 (%)) | Non-IDU IE (n = 357 (%)) | P value |
|---|---|---|---|
Women | 55 (33) | 119 (33) | 1.00 |
Men | 110 (67) | 238 (67) | 1.00 |
Age, mean (± SD); median (25th and 75th percentiles) | 41.6 (11.9); 44 (31, 50) | 64.3 (16.4); 67 (56, 76) | < 0.01 |
Predisposing factors | |||
Bicuspid aortic valve | 0 (0) | 20 (6) | < 0.01 |
Prosthetic valve | 12 (7) | 83 (23) | < 0.01 |
CIED | 2 (1) | 38 (11) | < 0.01 |
Rheumatic heart disease | 0 (0) | 2 (1) | 1.00 |
Congenital heart disease | 0 (0) | 8 (2) | 0.06 |
History of IE | 49 (30) | 34 (10) | < 0.01 |
Known valvular disease | 3 (2) | 78 (22) | < 0.01 |
Heart failure before or under IE treatment | 19 (12) | 45 (13) | 0.72 |
Patients fulfilling Duke’s major criteria | |||
Blood culture positive for IE | 144 (87) | 304 (85) | 0.78 |
Echocardiography positive for IEa | 165 (100) | 287 (80) | < 0.01 |
Patients fulfilling Duke’s minor criteria | |||
Fever | 150 (91) | 304 (85) | 0.07 |
Vascular phenomena | 101 (61) | 120 (34) | < 0.01 |
Spondylitis | 25 (15) | 30 (9) | 0.02 |
Pulmonary septic emboli | 55 (33) | 11 (3) | < 0.01 |
New heart murmur | 20 (12) | 63 (18) | 0.11 |
Immunological phenomenon | 2 (1) | 19 (5) | 0.03 |
Outcomes | |||
Surgery | 27 (16) | 121 (34) | < 0.01 |
In-hospital mortality | 7 (4) | 27 (8) | 0.15 |
Relapse during follow upb | 1 (0) | 4 (1) | 1.00 |
Re-infected during follow upb | 2 (1) | 1 (0) | 0.24 |